BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8000111)

  • 1. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM).
    Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y
    Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.
    Barth A; Probst P; Bürgi H
    J Endocrinol Invest; 1991 Mar; 14(3):209-12. PubMed ID: 2071823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
    Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
    Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine therapy and Graves' ophthalmopathy.
    Bartalena L; Marcocci C
    Thyroid; 1996 Jun; 6(3):253. PubMed ID: 8837336
    [No Abstract]   [Full Text] [Related]  

  • 6. (131)I and thyroid-associated ophthalmopathy.
    Rasmussen AK; Nygaard B; Feldt-Rasmussen U
    Eur J Endocrinol; 2000 Aug; 143(2):155-60. PubMed ID: 10913933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
    Tallstedt L; Lundell G; Blomgren H; Bring J
    Eur J Endocrinol; 1994 May; 130(5):494-7. PubMed ID: 8180678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
    Kung AW; Yau CC; Cheng A
    J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does radioiodine cause the ophthalmopathy of Graves' disease?
    McDougall IR
    Nucl Med Commun; 1993 Feb; 14(2):79-81. PubMed ID: 8429998
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with Graves disease.
    Sarui H; Sano A; Maruyama T; Nakashima K; Takeda N; Yasuda K
    Am J Med Sci; 2002 Aug; 324(2):109-14. PubMed ID: 12186105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine and the immune system.
    DeGroot LJ
    Thyroid; 1997 Apr; 7(2):259-64. PubMed ID: 9133697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.
    Tallstedt L; Lundell G
    Thyroid; 1997 Apr; 7(2):241-5. PubMed ID: 9133694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing Graves' ophthalmopathy.
    Wiersinga WM
    N Engl J Med; 1998 Jan; 338(2):121-2. PubMed ID: 9420345
    [No Abstract]   [Full Text] [Related]  

  • 17. Graves' disease induced by Na(131)I therapy for toxic multinodular goitre.
    van Leussen JJ; Edelbroek MA; Talsma MA; de Heide LJ
    Neth J Med; 2000 Nov; 57(5):194-7. PubMed ID: 11185482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease.
    Jensen BE; Bonnema SJ; Hegedüs L
    Eur J Endocrinol; 2005 Jul; 153(1):15-21. PubMed ID: 15994741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation.
    Höfle G; Moncayo R; Baldissera I; Pfister R; Finkenstedt G
    Thyroid; 1995 Dec; 5(6):477-80. PubMed ID: 8808100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
    Salvatore D; Fenzi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.